There is provided a therapeutic instrument, for storing a sheet-type therapeutic substance to which a liquid is delivered, and delivering the stored therapeutic substance to an affected part, including: a nozzle member 23 having an opening 34 on a tip end of a tubular part 31 in which the therapeutic substance can be stored, for charging and discharging the therapeutic substance; and a syringe unit 22 that selectively causes a negative pressure and a positive pressure to act in the tubular part 31 through a hole of a valve member 27, wherein the space 33 of the tubular part 31 is the space for sucking the therapeutic substance into the tubular part 31 together with the liquid by causing the negative pressure in the tubular part 31 by the syringe unit 22 when the therapeutic substance is stored therein, and is the space for pushing out the therapeutic substance to outside of the tubular part 31 together with the liquid by causing the positive pressure to act in the tubular part 31 by the syringe unit 22 when the stored therapeutic substance is delivered to the affected part.

Treatments and devices for generating and using interleukin-1 receptor antagonist (IL-1ra). An implantable device is loaded with adipose tissue and/or white blood cells and inserted into an inflammation site in a patient to produce interleukin-1 receptor antagonist in vivo. The implantable device has an enclosed or substantially enclosed body that defines an internal space. At least a portion of the body comprises a first bioresorbable material and a second bioresorbable material is within the internal space along with one or more voids. The second bioresorbable material includes an activation surface to activate adipose tissue and/or white blood cells loaded into the device to produce IL-1ra.

Drug depot delivery devices and methods for delivering a drug depot to a site beneath the skin of a patient are provided. In various embodiments the device has a housing having a top housing end, and a bottom housing end. The housing defines a housing channel. The device has a drug cartridge defining a depot channel aligned with the housing channel and configured to slidably accept the drug depot. The drug cartridge has at least a first occluding device configured to occlude the depot channel at a first position such that the drug depot cannot pass through the depot channel without force applied to the drug depot sufficient to deflect the first occluding device. The bottom end of the housing has a coupling configuration for engaging a cannula. A plunger has a push rod to expel the drug depot through the occluding device and the cannula.

The invention pertains to an applicator (1) for inserting an implant, in particular a rod-like implant (2) containing an active substance, under the skin of a human or animal, comprising a housing (3), a cannula (6), a cannula holder (9), an implant (2) accommodated inside the cannula (6) and/or the cannula holder (9), a protective cover (7) for the cannula (6), and a mechanism (22, 23, 7) which, at least after the cover (7) has been removed from the cannula (6), secures the implant (2) inside the cannula (6) and/or cannula holder (9). The mechanism (22, 23, 7) disengages the implant (2) during insertion of the cannula (6) or after the cannula (6) has been inserted. Substantially no lateral force will be exerted during the expelling of the implant from the cannula.

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade within the wall to release the drug to produce a therapeutic effect. The preparation can be coupled to a delivery mechanism having one or more balloons or other expandable devices which are expandable responsive to a condition in the small intestine or other GI lumen to advance the preparation out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

Glaucoma can be treated by implanting an intraocular shunt into an eye. The eye has an anterior chamber and sclera. A shunt can be placed into the eye to establish fluid communication from the anterior chamber of the eye through the sclera, and a pharmaceutical or biological agent can be administered to the eye.

A carrier device and methods of use are described. The device and methods are directed toward implanting in biological tissue and for releasing a medical payload or functional material in biological tissue according to a remote magnetic trigger. The carrier device has a cavity with an opening through an external surface of the device. The carrier device includes at least one moveable, magnetic element sensitive to a magnetic field gradient. When a magnetic field gradient, rotating magnetic field, or uniform magnetic field, or a combination of thereof is applied to the tissue, the moveable magnetic element provides release of the medical payload or functional material through the cavity opening. In some embodiments, payload release can be started, stopped, and restarted at a later time or place. In addition to payload release, devices of this invention are equipped with a propelling element, the propelling element is responsive to external stimuli that enables propulsion and navigation of the device.

A minimally traumatic trocar apparatus for delivering one or more medication pellets to a subcutaneous insertion site is described. The minimally traumatic trocar apparatus includes a blunt cannula and an obturator. The blunt cannula includes a tubular cannula body having an anterior end with a surface that has a smooth edge. The blunt cannula also includes a medication slot disposed along the tubular cannula body and an inner diameter that is at least 3 millimeters (mm). The obturator includes an anterior rounded tip. The obturator body is inserted within the tubular cannula body so that the obturator extends through the tubular cannula body so that the anterior rounded tip of the obturator extends past the anterior end of the tubular cannula body.

A minimally traumatic trocar system is described. The trocar system includes a cannula, a plastic obturator, and hydrodissection microcannula. The cannula includes a tubular cannula body and blunt anterior surface. The obturator includes an anterior rounded tip. The hydrodissection microcannula includes an anterior rounded tip and an opening proximate to the anterior rounded tip. The cannula and plastic obturator assemble to form a minimally traumatic trocar by passing the plastic obturator through an interior passage of a tubular cannula body of the cannula. The hydrodissection microcannula probes an incision to form an insertion path while causing minimal trauma. The assembled trocar probes the incision along the insertion path to reach a delivery site within subcutaneous tissue. The plastic obturator withdraws from the cannula and at least one medication pellet is loaded within the interior passage. The plastic obturator pushes the medication pellet(s) through the interior passage to the delivery site and deposits the medication pellet(s) within the subcutaneous tissue.

Self-righting articles, such as self-righting capsules for administration to a subject, are generally provided. In some embodiments, the self-righting article may be configured such that the article may orient itself relative to a surface (e.g., a surface of a tissue of a subject). The self-righting articles described herein may comprise one or more tissue engaging surfaces configured to engage (e.g., interface with, inject into, anchor) with a surface (e.g., a surface of a tissue of a subject). In some embodiments, the self-righting article may have a particular shape and/or distribution of density (or mass) which, for example, enables the self-righting behavior of the article. In some embodiments, the self-righting article may comprise a tissue interfacing component and/or a pharmaceutical agent (e.g., for delivery of the active pharmaceutical agent to a location internal of the subject). In some cases, upon contact of the tissue with the tissue engaging surface of the article, the self-righting article may be configured to release one or more tissue interfacing components. In some cases, the tissue interfacing component is associated with a self-actuating component. For example, the self-righting article may comprise a self-actuating component configured, upon exposure to a fluid, to release the tissue interfacing component from the self-righting article. In some cases, the tissue interfacing component may comprise and/or be associated with the pharmaceutical agent (e.g., for delivery to a location internal to a subject).